Company Overview and News

1
PDEX / Pro-Dex, Inc. null

2018-05-31 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C7!E+UA2968O5ULQ(#,@,5T^/G-T#278P:08F-X+)$+":9"#)* !A M)P#)_S=_,3 !S;\[email protected]&*49G\S\ X^Q- @ $ 6
PDEX

1
PDEX / Pro-Dex, Inc. null

2018-05-31 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#$O2VED%[email protected]," P(#8Q,B W.3)=("]#;VYT96YTU55
PDEX

2
PDEX / Pro-Dex, Inc. SPECIALIZED DISCLOSURE REPORT

2018-05-31 sec.gov
SPECIALIZED DISCLOSURE REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PDEX

1
1
Pro-Dex, Inc. Announces Fiscal 2018 Third Quarter and Nine-Month Results

2018-05-10 accesswire
IRVINE, CA / ACCESSWIRE / May 10, 2018 / PRO-DEX, INC. (NASDAQ: PDEX) today announced financial results for its fiscal 2018 third quarter ended March 31, 2018. The Company also filed its Quarterly Report on Form 10-Q for the third quarter of fiscal year 2018 with the Securities and Exchange Commission today.
PDEX

4
PDEX / Pro-Dex, Inc. QUARTERLY REPORT (Quarterly Report)

2018-05-10 sec.gov
Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PDEX

2
1
2
1
PDEX / Pro-Dex, Inc. AMENDED ANNUAL REPORT (Annual Report)

2018-04-09 sec.gov
Amended Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PDEX

1
PDEX / Pro-Dex, Inc. AMENDED ANNUAL REPORT (Annual Report)

2018-03-23 sec.gov
Amended Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PDEX

1

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Silicon Investor Message Boards

This table lists all message boards related to PDEX / Pro-Dex, Inc. on message board site Silicon Investor.

Pro-Dex Inc. (PDEX) PDEX- Any thoughts on this one?
CUSIP: 74265M205